Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06329687 Active, not recruiting - Dry Eye Clinical Trials

A Phase 4 Study Evaluating the Safety of the Nasal Pump

Start date: February 21, 2024
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the safety of the Tyrvaya nasal pump.

NCT ID: NCT06328673 Active, not recruiting - Clinical trials for Advanced Solid Tumor

A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Start date: March 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to define a safe and effective dose of DM919 for participants with solid tumors The main questions it aims to answer are: What is the safe and effective dose of DM919 when used alone or in combination with pembrolizumab? What cancers can be treated effectively with DM919 alone or in combination with pembrolizumab?? Participants will be asked to attend clinic and be given a intravenous infusion of DM919 or DM-919 in combination with pembrolizumab. They will have blood tests and other assessments to measure whether DM-919 will have the effect on tumors.

NCT ID: NCT06320028 Active, not recruiting - Depression Clinical Trials

Altering Default Mode Network Activity With Transcranial Focused Ultrasound to Reduce Depressive Symptoms

DMNtFUS
Start date: April 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Depression is a leading cause of disability worldwide, affecting roughly 21 million adults. Repetitive Negative Thought (RNT) has been identified as a potential maintaining factor in depression, such that those who exhibit higher degrees of RNT endorse greater symptoms. Research also suggests that the Default Mode Network (DMN), responsible for self-referential processing, plays an important role in depression wherein it has been linked to RNT. In depressed individuals, this network appears to be hyper-connected, or "too connected", within itself which, in turn, is thought to promote RNT. Half of depressed individuals are treatment-resistant, creating a critical need to identify more effective interventions derived from a better mechanistic understanding of the development and maintenance of depression. Non-invasive Transcranial-Focused Ultrasound Stimulation (tFUS) is promising for the treatment of depression. tFUS directs a low-intensity (nonthermal) focused ultrasound beam that passes safely through the skull. Compared to other noninvasive neuromodulation approaches, tFUS can target deeper brain regions with high spatial precision. The present study is an exploratory non-blinded single treatment study to investigate whether tFUS targeting a major hub of the DMN, the anterior-medial prefrontal cortex, can improve depression symptoms and reduce RNT. Twenty depressed individuals with high RNT (75th percentile) will complete up to eleven ultrasound sessions targeting the anterior medial prefrontal cortex, a hub of the brain's default mode network that has been found to be hyper-connected in depression. MRI scans will be obtained before the first and after the last ultrasound sessions. Based on previous literature, it is predicted that depression interview ratings and self-report symptoms will decrease after the intervention, and also that DMN connectivity will decrease following intervention.

NCT ID: NCT06314490 Active, not recruiting - Genetic Disease Clinical Trials

Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A

Start date: February 16, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with SCN2A associated developmental epileptic encephalopathy

NCT ID: NCT06314438 Active, not recruiting - Autism Clinical Trials

Culturally-Responsive Curriculum for Caregivers With Children at Autism Likelihood

Start date: December 15, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to examine how helpful and relevant the Family Care Project workbook is for families from culturally and linguistically diverse backgrounds who have a young child at autism likelihood. The main questions this trial aims to answer are: - Is the Family Care Project workbook useful for families? - Is the Family Care Project workbook easy to use? - Can the Family Care Project be implemented by non-profit workers who do not have health backgrounds? Participants will complete surveys that elicit their feedback on their use of the workbook.

NCT ID: NCT06308822 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial tests how well JNJ-42756493 (erdafitinib) works in treating patients with tumors that have more copies of the FGFR gene than is normal (amplification). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply.

NCT ID: NCT06307301 Active, not recruiting - Clinical trials for Amyotrophic Lateral Sclerosis

Study in ALS With Abatacept & IL-2

Start date: October 28, 2021
Phase: Phase 1
Study type: Interventional

In Amyotrophic Lateral Sclerosis (ALS), the reduction of regulatory T-lymphocyte (Treg) numbers and suppressive function correlates with rapid disease progression. The investigator completed a phase 1 study of infusions of expanded autologous Tregs in combination with subcutaneous IL-2 injections in ALS patients, which showed enhancement of Treg numbers and suppressive function in vivo. The enhanced Treg suppressive function correlated strongly with slowing and stabilization of disease progression. Drugs that enhance endogenous Treg numbers and suppressive function may also stabilize disease in ALS. This phase 1 study aims to determine whether the combination therapy of subcutaneous IL-2 and abatacept (Orencia®) is safe and well-tolerated in 6 patients with ALS, and whether the therapy enhances Treg numbers and suppressive function in vivo.

NCT ID: NCT06300242 Active, not recruiting - Clinical trials for Influenza Vaccination

Incentives for Influenza Vaccination

Start date: January 17, 2024
Phase: N/A
Study type: Interventional

In this work, we are assessing the impact of messaging with or without a $50 financial incentive on influenza vaccination rates in a county health system. Our main hypothesis is that a message with a $50 financial incentive will increase vaccination rates relative to a control/"treatment as usual" group. We further hypothesize that the financial incentive will increase vaccination rates relative to the message only arm.

NCT ID: NCT06297187 Active, not recruiting - Clinical trials for Condylomata Acuminata

Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study

Start date: February 23, 2024
Phase:
Study type: Observational

The study is a single arm, retrospective, single-center, post market registry. The purpose of this Registry is to collect data to demonstrate the safety and performance of CUSA® for the treatment of Vulvar Intraepithelial Neoplasia (VIN) and condyloma acuminata.

NCT ID: NCT06292026 Active, not recruiting - Diabetic Foot Ulcer Clinical Trials

Efficacy of ProgenaMatrix™ in the Management of DFUs

Start date: March 14, 2022
Phase: N/A
Study type: Interventional

This multicenter study will collect data to determine closure time for diabetic ulcers when following protocol parameters and treatment with ProgenaMatrix™.